Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) (THYROSCOPE-TED)
28. maj 2026 opdateret af: THYROSCOPE INC.
Prospective Observational Study of Smartphone-Based Self-Monitoring Using an Artificial Intelligence Solution During Non-Surgical Treatment for Thyroid Eye Disease
This prospective observational study evaluates the feasibility and clinical utility of a smartphone-based artificial intelligence (AI) self-monitoring system in adults with thyroid eye disease (TED) undergoing non-surgical treatment.
Eligible participants will use their own smartphones and the study application (Glandy) to perform at least weekly home monitoring consisting of a symptom questionnaire (diplopia, pain on visual analog scale) and a standardized frontal facial photograph.
AI-derived outputs (Glandy CAS, Glandy EXO, Glandy LID) obtained at routine clinic visits will be compared with standard clinician assessments (CAS total score, Hertel exophthalmometry, MRD1/MRD2).
AI outputs will not be used for real-time clinical decision-making during the study.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Thyroid eye disease (TED) is an autoimmune inflammatory disorder most commonly associated with Graves' disease. Clinical manifestations include conjunctival injection, eyelid swelling, eyelid retraction, proptosis, diplopia, and altered ocular appearance. TED typically progresses through an active inflammatory phase of approximately 6-12 months before transitioning to a relatively inactive phase, although interval worsening may occur. Because treatment response can change dynamically, timely assessment of disease activity and severity is important for monitoring.
In current practice, TED activity and severity are primarily assessed during in-person visits using the Clinical Activity Score (CAS), Hertel exophthalmometry, and eyelid measurements (MRD1/MRD2). These assessments are episodic and may not capture interval change between visits.
Recent advances in AI have enabled image-based quantification of TED-related features from facial or periocular photographs. The AI-based monitoring system evaluated here has three analytic components: Glandy CAS (CAS-related outputs from photographs + symptom input), Glandy EXO (image-based exophthalmometric estimate), and Glandy LID (eyelid-related parameters including MRD measurements).
This prospective observational study will enroll approximately 200 adults with TED scheduled to initiate non-surgical treatment (intravenous methylprednisolone, oral corticosteroids, radiotherapy, or biologic therapy). Participants will perform at least weekly home-based self-monitoring (symptom entry + standardized frontal facial image) using their own smartphones and the study application. Baseline and end-of-treatment data will be required. At routine clinic visits, app-based image capture and symptom entry will also be performed to create clinic-matched assessments; AI-derived outputs will be compared with clinician-assessed TED parameters obtained the same day. At least two clinic-matched assessments per participant will be required for longitudinal evaluation. AI-generated outputs will not be used for real-time clinical decision-making.
Undersøgelsestype
Observationel
Tilmelding (Anslået)
200
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Jaemin Park
- Telefonnummer: +82 52-264-4154
- E-mail: jaemin.park@thyroscope.com
Studiesteder
-
-
California
-
San Jose, California, Forenede Stater, 95134
- 3003 North First Street #221
-
Kontakt:
- Jaemin Park CEO
- Telefonnummer: +82-52-264-4154
- E-mail: jaemin.park@thyroscope.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Adults (≥19 years) with clinically diagnosed TED who are scheduled to initiate active non-surgical treatment at participating ophthalmology sites.
Beskrivelse
Inclusion Criteria:
- Adults aged 19 years or older with a clinical diagnosis of thyroid eye disease (TED).
- Patients with TED scheduled to initiate active non-surgical treatment, including but not limited to intravenous methylprednisolone, oral corticosteroids, radiotherapy, or biologic therapy.
- Able to undergo baseline clinical assessment prior to initiation of the planned treatment course and expected routine follow-up evaluation during treatment, including an end-of-treatment assessment.
- Able and willing to use their own smartphone to complete the study application-guided symptom questionnaire and capture standardized frontal facial images throughout the study period.
- Willing to perform at least weekly home-based image capture and symptom reporting during the treatment course.
- Able to participate in routine in-person follow-up visits and expected to provide at least two clinic-matched assessments, including baseline and at least one post-baseline assessment.
- Voluntarily provides written informed consent to participate in the study.
Exclusion Criteria:
- Severe eyelid deformities, facial deformities, or other facial/periocular conditions that may interfere with standardized image acquisition or reliable AI-based image analysis.
- Unable to use the study application or smartphone-based image capture procedure adequately for protocol-required self-monitoring.
- Undergoing or planning to undergo surgical treatment for TED as the primary treatment modality during the study period.
- History of ocular, eyelid, or orbital surgery within 3 months prior to enrollment.
- Any medical, psychiatric, cognitive, or other condition that, in the investigator's judgment, may compromise protocol compliance, study participation, or data integrity.
- Any other condition that the investigator judges to make the patient inappropriate for participation.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
TED - Non-surgical treatment cohort
Adults with TED initiating non-surgical treatment who perform smartphone-based self-monitoring (weekly symptom entry + facial image capture) during the treatment course, with clinic-matched assessments at routine visits.
|
A smartphone application through which participants complete a symptom questionnaire (diplopia; pain by visual analog scale) and capture a standardized frontal facial photograph at least weekly during the treatment course, and additionally at each routine clinic visit. Submitted images are transmitted to a central analysis system for AI-based processing that generates three analytic outputs:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Agreement between Glandy CAS and clinician-assessed CAS total score
Tidsramme: At each clinic-matched visit (baseline through end-of-treatment, up to 12 months)
|
Agreement between AI-derived Clinical Activity Score (Glandy CAS) and clinician-assessed CAS total score at clinic-matched visits, using intraclass correlation coefficient (ICC), correlation analysis, and Bland-Altman analysis.
|
At each clinic-matched visit (baseline through end-of-treatment, up to 12 months)
|
|
Agreement between Glandy EXO and Hertel exophthalmometry
Tidsramme: At each clinic-matched visit (baseline through end-of-treatment, up to 12 months)
|
Agreement between AI-derived image-based exophthalmometric estimate (Glandy EXO, mm) and clinician-measured Hertel exophthalmometry absolute value (mm) at clinic-matched visits, using ICC, correlation, and Bland-Altman analysis.
|
At each clinic-matched visit (baseline through end-of-treatment, up to 12 months)
|
|
Agreement between Glandy LID and clinician-measured MRD1/MRD2
Tidsramme: At each clinic-matched visit (baseline through end-of-treatment, up to 12 months)
|
Agreement between AI-derived eyelid parameters (Glandy LID: MRD1 and MRD2 equivalents, mm) and clinician-measured MRD1 and MRD2 (mm) at clinic-matched visits, using ICC, correlation, and Bland-Altman analysis.
|
At each clinic-matched visit (baseline through end-of-treatment, up to 12 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Longitudinal change in AI-derived TED parameters
Tidsramme: Weekly home monitoring from baseline to end-of-treatment (up to 12 months)
|
Descriptive longitudinal change in Glandy CAS, Glandy EXO, and Glandy LID obtained from serial home-monitoring data during the non-surgical treatment course.
|
Weekly home monitoring from baseline to end-of-treatment (up to 12 months)
|
|
Concordance between AI-derived longitudinal trends and interval clinical change
Tidsramme: From baseline to end-of-treatment (up to 12 months)
|
Concordance between longitudinal AI-derived parameter trends and interval clinical change observed at routine follow-up, analyzed with descriptive paired comparisons and repeated-measures / mixed-effects approaches as appropriate.
|
From baseline to end-of-treatment (up to 12 months)
|
|
Feasibility: adherence to weekly home-based image capture
Tidsramme: Throughout treatment period (up to 12 months)
|
Proportion of participants performing at least weekly home-based facial image capture using the study application.
|
Throughout treatment period (up to 12 months)
|
|
Feasibility: adherence to symptom reporting
Tidsramme: Throughout treatment period (up to 12 months)
|
Number and proportion of completed in-app symptom reports (diplopia, VAS pain) relative to expected weekly submissions.
|
Throughout treatment period (up to 12 months)
|
|
Feasibility: completion of clinic-matched assessments
Tidsramme: Throughout treatment period (up to 12 months)
|
Number and proportion of participants completing ≥2 clinic-matched assessments including baseline and at least one post-baseline assessment.
|
Throughout treatment period (up to 12 months)
|
|
Relationship between patient-reported symptoms and AI-derived measurements
Tidsramme: Throughout treatment period (up to 12 months)
|
Association between patient-reported diplopia and VAS pain with AI-derived parameters over time, explored descriptively and with regression / mixed-effects models where appropriate.
|
Throughout treatment period (up to 12 months)
|
|
Clinical utility of serial AI-based monitoring between clinic visits
Tidsramme: Throughout treatment period (up to 12 months)
|
Ability of serial AI-derived monitoring to provide clinically useful adjunctive information regarding early improvement or interval worsening between routine clinic visits (descriptive).
|
Throughout treatment period (up to 12 months)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Descriptive analysis of additional image-derived periocular parameters
Tidsramme: Throughout treatment period (up to 12 months)
|
Ocular surface area (OSA), radial MRD-related parameters, and other eyelid-related image metrics obtained from patient-captured smartphone images.
|
Throughout treatment period (up to 12 months)
|
|
Exploratory AI-derived trend vs. treatment response
Tidsramme: Throughout treatment period (up to 12 months)
|
Exploratory assessment of whether AI-derived home-monitoring trends reflect treatment response over the course of non-surgical treatment.
|
Throughout treatment period (up to 12 months)
|
|
Real-world image data completeness and analyzability
Tidsramme: Throughout treatment period (up to 12 months)
|
Descriptive characterization of data completeness and AI-analyzable rate of patient-captured smartphone facial images in a real-world treatment setting.
|
Throughout treatment period (up to 12 months)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. juli 2026
Primær færdiggørelse (Anslået)
30. juni 2027
Studieafslutning (Anslået)
31. december 2027
Datoer for studieregistrering
Først indsendt
18. april 2026
Først indsendt, der opfyldte QC-kriterier
28. maj 2026
Først opslået (Faktiske)
3. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
3. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
28. maj 2026
Sidst verificeret
1. april 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Genetiske sygdomme, medfødte
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Øjensygdomme
- Øjensygdomme, arvelig
- Graves sygdom
- Eksophthalmos
- Orbitale sygdomme
- Struma
- Hyperthyroidisme
- Skjoldbruskkirtelsygdomme
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Graves Oftalmopati
Andre undersøgelses-id-numre
- THYROSCOPE-TED-2026-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
The dataset includes patient-captured smartphone facial photographs, which are inherently identifiable biometric data.
Public sharing of individual participant data (IPD) would pose a substantial risk of re-identification that cannot be fully mitigated by standard de-identification of tabular variables alone.
The informed consent obtained from participants and the IRB-approved protocol do not authorize broad third-party sharing of these facial images or associated individual-level records.
In addition, the study is conducted in the Republic of Korea and is subject to the Personal Information Protection Act (PIPA) and the Bioethics and Safety Act, which restrict external transfer of identifiable health and biometric information.
For these reasons, individual-level data will not be shared publicly.
Reasonable requests for scientifically justified collaborative analyses may be considered on a case-by-case basis, subject to a data-use agreement, sponsor approval, and applicable ethics appr
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ja
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .